MVP and MundiPharma cease Australian licensing agreement
30 October 2020
MVP and MundiPharma agree to cease distribution and licensing agreement in Australia
MVP today announced it has taken back the distribution rights for its pain relief drug Penthrox in the Australian market from MundiPharma. Since assigning the rights to Mundipharma a year ago, the global Mundipharma organisation has gone through a significant re-organisation, causing both companies to review their arrangements on a market by market basis.
Acting CEO, Max Johnston said “The separation of the MVP business from MundiPharma is collegial and friendly. We thank MundiPharma for their willingness to assist with the hand back of materials and the business as well as the efforts they have put into growing our customer base. We will resume servicing the business from 1st December 2020 and plan a smooth and orderly transition.”
For further information please click on the following link – ASX Announcement – Mundipharma Australia